Table 3.
Summary of immunoglobulin G4-related ophthalmic disease in different study
| Age# | Sex (male: female) | Bilateral disease (%) | Ocular adnexal involvements | Elevated* serum IgG4 (%) | Systemic IgG4-RD (%) | Disease relapse (%) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| LG (%) | Orbit (%) | EOM (%) | Nerve+ (%) | Other (%) | |||||||
| Sato et al., 2008 (n=21) | 60.4 (38-86) | 10:11 | 12/21 (57) | 16/21 (76) | 7/21 (33) | N/A | N/A | N/A | N/A | 6/21 (29) | 5 (28) |
| Kubota et al., 2010 (n=10) | 57.6 (38-73) | 5:5 | 8/10 (80) | 5/10 (50) | 2/10 (20) | 1/10 (10) | N/A | 4/10 (40) | 10/10 (100) | 7/10 (70) | 2 (20) |
| Plaza et al. 2011 (n=11) | 50.4 (30-70) | 6:5 | 6/11 (55) | 10/11 (90) | 2/11 (18) | 4/11 (36) | N/A | N/A | N/A | 5/11 (45) | 2 (18) |
| Go et al., 2012 (n=14) | 51.2 (20-72) | 7:7 | 10/14 (71) | 13/14 (93) | N/A | N/A | N/A | 1/14 (7) | 13/14 (93) | 6/14 (43) | 7 (50) |
| Takahira et al. 2012 (n=16) | 56.4 (41-76) | 8:8 | N/A | 16/16 (100) | N/A | 4/16 (25) | 5/16 (31) | N/A | 15/16 (94) | 14/16 (88) | 5 (31) |
| Koizumi et al., 2013 (n=12) | 60.9 (25-74) | 7:5 | 6/12 (50) | 12/12 (100) | 3/12 (25) | 6/12 (50) | 2/12 (17) | N/A | 12/12 (100) | 9/12 (75) | 2 (17) |
| Yu et al., 2015 (n=11) | 54.5 (21-75) | 7:4 | 7/11 (64) | 8/11 (73) | 4/11 (36) | 3/11 (27) | N/A | 1/11 (9) | 10/11 (91) | 8/11 (73) | 5 (45) |
| Overall (n=95) | 56.3 (20-86) | 50:45 | 49/79 (62) | 80/95 (84) | 18/95 (19) | 18/95 (19) | 7/95 (7) | 6/95 (6) | 60/63 (95) | 55/95 (58) | 28/95 (29) |
#Median (minimum-maximum), +Including traorbital nerve, supraorbital nerve, and optic nerve, *Serum IgG4 >135 mg/dL. N/A = Data not available or incomplete, IgG4 = Immunoglobulin G4, EOM = Extraocular muscle, LG = Lacrimal gland, RD = Related disease